Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

2'-Hydroxyflavanone induced changes in the proteomic profile of breast cancer cells.

Nagaprashantha LD, Singhal J, Chikara S, Gugiu G, Horne D, Awasthi S, Salgia R, Singhal SS.

J Proteomics. 2018 Sep 21. pii: S1874-3919(18)30346-4. doi: 10.1016/j.jprot.2018.09.005. [Epub ahead of print]

PMID:
30248461
2.

2'-Hydroxyflavanone effectively targets RLIP76-mediated drug transport and regulates critical signaling networks in breast cancer.

Nagaprashantha LD, Singhal J, Li H, Warden C, Liu X, Horne D, Awasthi S, Salgia R, Singhal SS.

Oncotarget. 2018 Apr 6;9(26):18053-18068. doi: 10.18632/oncotarget.24720. eCollection 2018 Apr 6.

3.

2'-Hydroxyflavanone inhibits in vitro and in vivo growth of breast cancer cells by targeting RLIP76.

Singhal J, Chikara S, Horne D, Salgia R, Awasthi S, Singhal SS.

Mol Carcinog. 2018 Dec;57(12):1751-1762. doi: 10.1002/mc.22894. Epub 2018 Sep 19.

PMID:
30136444
4.

2'-Hydroxyflavanone: A novel strategy for targeting breast cancer.

Singhal J, Nagaprashantha L, Chikara S, Awasthi S, Horne D, Singhal SS.

Oncotarget. 2017 Aug 24;8(43):75025-75037. doi: 10.18632/oncotarget.20499. eCollection 2017 Sep 26.

5.

Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer.

Simigdala N, Gao Q, Pancholi S, Roberg-Larsen H, Zvelebil M, Ribas R, Folkerd E, Thompson A, Bhamra A, Dowsett M, Martin LA.

Breast Cancer Res. 2016 Jun 1;18(1):58. doi: 10.1186/s13058-016-0713-5.

6.

Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers.

Watanabe T, Hida AI, Inoue N, Imamura M, Fujimoto Y, Akazawa K, Hirota S, Miyoshi Y.

Breast Cancer Res Treat. 2018 Feb;168(1):135-145. doi: 10.1007/s10549-017-4575-z. Epub 2017 Nov 22.

PMID:
29168063
7.

Translational opportunities for broad-spectrum natural phytochemicals and targeted agent combinations in breast cancer.

Dalasanur Nagaprashantha L, Adhikari R, Singhal J, Chikara S, Awasthi S, Horne D, Singhal SS.

Int J Cancer. 2018 Feb 15;142(4):658-670. doi: 10.1002/ijc.31085. Epub 2017 Nov 28. Review.

PMID:
28975625
8.

Growth hormone receptor blockade inhibits growth hormone-induced chemoresistance by restoring cytotoxic-induced apoptosis in breast cancer cells independently of estrogen receptor expression.

Minoia M, Gentilin E, Molè D, Rossi M, Filieri C, Tagliati F, Baroni A, Ambrosio MR, degli Uberti E, Zatelli MC.

J Clin Endocrinol Metab. 2012 Jun;97(6):E907-16. doi: 10.1210/jc.2011-3340. Epub 2012 Mar 22.

PMID:
22442272
9.

Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases.

Heitz F, Harter P, Lueck HJ, Fissler-Eckhoff A, Lorenz-Salehi F, Scheil-Bertram S, Traut A, du Bois A.

Eur J Cancer. 2009 Nov;45(16):2792-8. doi: 10.1016/j.ejca.2009.06.027. Epub 2009 Jul 28.

PMID:
19643597
10.

Leptin-signaling inhibition results in efficient anti-tumor activity in estrogen receptor positive or negative breast cancer.

Rene Gonzalez R, Watters A, Xu Y, Singh UP, Mann DR, Rueda BR, Penichet ML.

Breast Cancer Res. 2009;11(3):R36. doi: 10.1186/bcr2321. Epub 2009 Jun 16.

11.

Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance.

Brufsky AM, Dickler MN.

Oncologist. 2018 May;23(5):528-539. doi: 10.1634/theoncologist.2017-0423. Epub 2018 Jan 19. Review.

PMID:
29352052
12.

The association between body mass index and immunohistochemical subtypes in breast cancer.

Sahin S, Erdem GU, Karatas F, Aytekin A, Sever AR, Ozisik Y, Altundag K.

Breast. 2017 Apr;32:227-236. doi: 10.1016/j.breast.2016.09.019. Epub 2016 Oct 15.

PMID:
27756509
13.

Clinicopathological significance and potential drug target of CDH1 in breast cancer: a meta-analysis and literature review.

Huang R, Ding P, Yang F.

Drug Des Devel Ther. 2015 Sep 18;9:5277-85. doi: 10.2147/DDDT.S86929. eCollection 2015. Review.

14.

[Survival of patients with metastatic breast cancer according to pathological types of tumors].

Sánchez R C, Acevedo C F, Petric G M, Galindo A H, Domínguez C F, León R A, Razmilic V D, Ceballos C, Espinoza F, Navarro O ME, Oddó B D, Camus A M.

Rev Med Chil. 2014 Apr;142(4):428-35. doi: 10.4067/S0034-98872014000400003. Spanish.

15.

Computational Inferences of the Functions of Alternative/Noncanonical Splice Isoforms Specific to HER2+/ER-/PR- Breast Cancers, a Chromosome 17 C-HPP Study.

Menon R, Panwar B, Eksi R, Kleer C, Guan Y, Omenn GS.

J Proteome Res. 2015 Sep 4;14(9):3519-29. doi: 10.1021/acs.jproteome.5b00498. Epub 2015 Jul 23.

16.

The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours.

El Ansari R, Craze ML, Miligy I, Diez-Rodriguez M, Nolan CC, Ellis IO, Rakha EA, Green AR.

Breast Cancer Res. 2018 Mar 22;20(1):21. doi: 10.1186/s13058-018-0946-6.

17.

Breast cancer subtype approximations and loco-regional recurrence after immediate breast reconstruction.

Kneubil MC, Brollo J, Botteri E, Curigliano G, Rotmensz N, Goldhirsch A, Lohsiriwat V, Manconi A, Martella S, Santillo B, Petit JY, Rietjens M.

Eur J Surg Oncol. 2013 Mar;39(3):260-5. doi: 10.1016/j.ejso.2012.12.004. Epub 2013 Jan 10.

PMID:
23313014
18.

Resistance to Targeted Therapies in Breast Cancer.

Braga S.

Methods Mol Biol. 2016;1395:105-36. doi: 10.1007/978-1-4939-3347-1_8. Review.

PMID:
26910072
19.

PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials.

Dey N, De P, Leyland-Jones B.

Pharmacol Ther. 2017 Jul;175:91-106. doi: 10.1016/j.pharmthera.2017.02.037. Epub 2017 Feb 16. Review.

PMID:
28216025
20.

Estrogen regulates miRNA expression: implication of estrogen receptor and miR-124/AKT2 in tumor growth and angiogenesis.

Jiang CF, Li DM, Shi ZM, Wang L, Liu MM, Ge X, Liu X, Qian YC, Wen YY, Zhen LL, Lin J, Liu LZ, Jiang BH.

Oncotarget. 2016 Jun 14;7(24):36940-36955. doi: 10.18632/oncotarget.9230.

Supplemental Content

Support Center